T-cell receptor-engineered T cells for cancer treatment: current status and future directions.
10.1007/s13238-016-0367-1
- Author:
Yu PING
1
;
Chaojun LIU
1
;
Yi ZHANG
2
Author Information
1. Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
2. Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. yizhang@zzu.edu.cn.
- Publication Type:Journal Article
- Keywords:
T-cell receptor;
TCR-engineered T cells;
neoantigen;
tumor antigen;
tumor microenvironment
- MeSH:
Animals;
Antigens, Neoplasm;
immunology;
metabolism;
Humans;
Neoplasms;
immunology;
metabolism;
Receptors, Antigen, T-Cell;
genetics;
metabolism;
T-Lymphocytes;
immunology;
metabolism
- From:
Protein & Cell
2018;9(3):254-266
- CountryChina
- Language:English
-
Abstract:
T-cell receptor (TCR)-engineered T cells are a novel option for adoptive cell therapy used for the treatment of several advanced forms of cancer. Work using TCR-engineered T cells began more than two decades ago, with numerous preclinical studies showing that such cells could mediate tumor lysis and eradication. The success of these trials provided the foundation for clinical trials, including recent clinical successes using TCR-engineered T cells to target New York esophageal squamous cell carcinoma (NY-ESO-1). These successes demonstrate the potential of this approach to treat cancer. In this review, we provide a perspective on the current and future applications of TCR-engineered T cells for the treatment of cancer. Our summary focuses on TCR activation and both pre-clinical and clinical applications of TCR-engineered T cells. We also discuss how to enhance the function of TCR-engineered T cells and prolong their longevity in the tumor microenvironment.
